1. Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?

   • Alessandra Modena
   • Francesco Massari
   • Giampaolo Tortora

   Review Article 05 February 2016 Pages: 431 - 446

   

2. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development

   • Jun Gong
   • Gauri Kelekar
   • Monica Mita

   Review Article 11 February 2016 Pages: 447 - 467

   

3. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints

   • Maria Alsina
   • Markus Moehler
   • Josep Tabernero

   Review Article 16 February 2016 Pages: 469 - 477

   

4. Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors

   • Amparo Sanchez-Gastaldo
   • Reyes Gonzalez-Exposito
   • Rocío Garcia-Carbonero

   Review Article 18 February 2016 Pages: 479 - 487

   

5. Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

   • Mario Scartozzi
   • Loic Vincent
   • Stefano Cascinu

   Review Article 13 July 2016 Pages: 489 - 500

   

6. Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis

   • Chenxi Hu
   • Xiaodong Jiang

   Review Article 26 February 2016 Pages: 501 - 505

   

7. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts

   • J. Rolff
   • M. Becker
   • I. Fichtner

   Original Research Article 28 January 2016 Pages: 507 - 514

   

8. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

   • Christos Chouaid
   • Isabelle Borget
   • Mondher Toumi

   Original Research Article Open access 01 February 2016 Pages: 515 - 534

   

9. Novel TNF-related Apoptotic-inducing Ligand-based Immunotoxin for Therapeutic Targeting of CD25 Positive Leukemia

   • Jayaprakasam Madhumathi
   • Surapally Sridevi
   • Rama Shanker Verma

   Original Research Article 17 March 2016 Pages: 535 - 547

   

10. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy

    • E. Bondon-Guitton
    • S. Combret
    • J. L. Montastruc

    Short Communication 19 February 2016 Pages: 549 - 552

    

11. Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab

    • Jeremy W. Vandiver
    • Zachary Singer
    • Cara Harshberger

    Therapy in Practice 04 March 2016 Pages: 553 - 556

    

12. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report

    • Andrew J. Dooley
    • Avinash Gupta
    • Mark R. Middleton

    Therapy in Practice Open access 09 February 2016 Pages: 557 - 563

13. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

    • Sandrine Faivre
    • Armand de Gramont
    • Eric Raymond

    Commentary 21 March 2016 Pages: 565 - 567